StockMacro
Company, fund or insider

Help

Menu

Black Diamond Therapeutics

$1.31 -44% in 6 monthsMarket cap $75.3M

BDTX on XNAS, Health Care, Black Diamond Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 66% in a year to $1.31 while cash of $102M exceeds the $80M market value.

  • BadNet loss of $44.1M over the last 12 months despite $102M cash
  • BadShort sellers hold 8.9% of shares, up 2.1% on two weeks earlier
  • GoodInstitutional holders rose to 107 from 94 last quarter, up 14%

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
21
Website
blackdiamondtherapeutics.com
Listed
Nasdaq, US
Last results
10 Nov 2026
Next results
expected around 15 Mar 2027 (an estimate: a year ago it reported on 16 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $10.0M.
Quarter to 31 Dec 2021: revenue –, net income -$25.9MQuarter to 31 Mar 2022: revenue –, net income -$25.5MQuarter to 30 Jun 2022: revenue –, net income -$22.9MQuarter to 30 Sep 2022: revenue –, net income -$21.7MQuarter to 31 Dec 2022: revenue –, net income -$21.1MQuarter to 31 Mar 2023: revenue –, net income -$20.9MQuarter to 30 Jun 2023: revenue –, net income -$19.2MQuarter to 30 Sep 2023: revenue –, net income -$23.0MQuarter to 31 Dec 2023: revenue –, net income -$19.4MQuarter to 31 Mar 2024: revenue $0, net income -$18.2MQuarter to 31 Mar 2024: revenue $0, net income -$18.2MQuarter to 30 Jun 2024: revenue $0, net income -$19.9MQuarter to 30 Jun 2024: revenue $0, net income -$19.9MQuarter to 30 Sep 2024: revenue $0, net income -$15.6MQuarter to 30 Sep 2024: revenue $0, net income -$15.6MQuarter to 31 Dec 2024: revenue $0, net income -$16.0MQuarter to 31 Dec 2024: revenue $0, net income -$16.0MQuarter to 31 Mar 2025: revenue $70.0M, net income $56.5MQuarter to 31 Mar 2025: revenue $70.0M, net income $56.5MQuarter to 30 Jun 2025: revenue $0, net income -$10.6MQuarter to 30 Jun 2025: revenue $0, net income -$10.6MQuarter to 30 Sep 2025: revenue $0, net income -$8.5MQuarter to 30 Sep 2025: revenue $0, net income -$8.5MQuarter to 31 Dec 2025: revenue $0, net income -$15.1MQuarter to 31 Dec 2025: revenue $0, net income -$15.1MQuarter to 31 Mar 2026: revenue $0, net income -$9.0MQuarter to 31 Mar 2026: revenue $0, net income -$9.0MQuarter to 30 Jun 2026: revenue $0, net income -$9.9MQuarter to 30 Jun 2026: revenue $0, net income -$9.9MQuarter to 30 Sep 2026: revenue $0, net income -$10.0MQuarter to 30 Sep 2026: revenue $0, net income -$10.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $70.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$10.0M
30 Jun 2026$0-$9.9M
31 Mar 2026$0-$9.0M
31 Dec 2025$0-$15.1M
30 Sep 2025$0-$8.5M
30 Jun 2025$0-$10.6M
31 Mar 2025$70.0M$56.5M
31 Dec 2024$0-$16.0M
30 Sep 2024$0-$15.6M
30 Jun 2024$0-$19.9M
31 Mar 2024$0-$18.2M
31 Dec 2023–-$19.4M
30 Sep 2023–-$23.0M
30 Jun 2023–-$19.2M
31 Mar 2023–-$20.9M
31 Dec 2022–-$21.1M
30 Sep 2022–-$21.7M
30 Jun 2022–-$22.9M
31 Mar 2022–-$25.5M
31 Dec 2021–-$25.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – $70.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$44.1M $21.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.76 $0.36
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – 16.9% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – 30.7% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -41.1% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $102.0M $135.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$102.0M (net cash) -$135.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.53
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.85 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Black Diamond TherapeuticsBDTX (this company) $75.3Mloss–––
Cardiff OncologyCRDF $66.3Mloss119+12%–
Tenaya TherapeuticsTNYA $65.3Mloss–––
Atara BiotherapeuticsATRA $64.5Mloss16.3-97%-369%
Zura BioZURA $89.6Mloss–––
Neumora TherapeuticsNMRA $63.0Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+14%

107 13F filers vs 94

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

66%

37.7M shares held by 13F filers (30 Sep 2026) of 57.5M outstanding (5 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.9%

5.1M shares sold short (30 Oct 2026) of 57.5M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.9

5.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+2.1%

5.0M shares sold short in the report before, 5.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.0×

6 articles in the last 7 days; its usual week has 1.

Price $1.31 on 20 Nov 2026, -66% over 12 months (12-month range $1.31 to $3.87)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: -$12.0M).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 107 13F filers reported holding it in the latest 13F quarter, +22% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
7 Oct 20248-K and other filingsDirector or officer change
7 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Apr 20248-K and other filingsDirector or officer change
18 Jan 20248-K and other filingsDirector or officer change
18 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jan 2024Sharp changeShort interest spike: short interest spike, 3.6M vs usual 2.0M (2023-12-29); 1.7x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 3.6M vs usual 2.0M (2023-12-15); 1.8x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 3.4M vs usual 2.0M (2023-11-30); 1.7x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 3.4M vs usual 2.0M (2023-11-15); 1.7x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 3.4M vs usual 2.0M (2023-10-31); 1.6x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 3.0M vs usual 2.0M (2023-10-13); 1.3x the same period a year earlier
18 Sep 20238-K and other filingsDirector or officer change
18 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 9.50 (2023-06-30); 2.5x the same period a year earlier
1 Aug 2023Sharp changeShort interest spike: short interest spike, 3.2M vs usual 2.0M (2023-07-14); 1.3x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 5.2M vs usual 2.0M (2023-06-30); 2.0x the same period a year earlier
8 Jul 2023Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 24.2M)
19 Dec 20228-K and other filingsDirector or officer change
19 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Apr 20228-K and other filingsDirector or officer change
7 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Apr 2022: $2.9M published
Month from 1 Jul 2022: $61K published
Month from 1 Oct 2022: $312K published
Month from 1 Nov 2022: $960K published
Month from 1 Dec 2022: $72K published
Month from 1 Jun 2023: $9.4M published
Month from 1 Jul 2023: $14.7M published
Month from 1 Oct 2023: $936K published
Month from 1 Aug 2024: -$1.4M published
Month from 1 Mar 2025: -$12.0M published
Revenue per quarter
Quarter ended 31 Mar 2024: $0; public on 13 May 2025
Quarter ended 30 Jun 2024: $0; public on 8 Aug 2025
Quarter ended 30 Sep 2024: $0; public on 7 Nov 2025
Quarter ended 31 Dec 2024: $0; public on 17 Mar 2026
Quarter ended 31 Mar 2025: $70.0M; public on 13 May 2025
Quarter ended 30 Jun 2025: $0; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 17 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $0; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 11 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $333K, +206% on a year earlier; public on 18 Mar 2022
Quarter ended 31 Mar 2022: $7K, -82% on a year earlier; public on 12 May 2022
Quarter ended 30 Jun 2022: $193K, -77% on a year earlier; public on 10 Aug 2022
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $0, -100% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $33K; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $0; public on 13 Mar 2024
Quarter ended 31 Dec 2024: $0; public on 7 Mar 2025
Institutional holders (13F filers)
31 Dec 2021 report: 83; public on 14 Feb 2022
31 Mar 2022 report: 81; public on 16 May 2022
30 Jun 2022 report: 70; public on 15 Aug 2022
30 Sep 2022 report: 65; public on 14 Nov 2022
31 Dec 2022 report: 55; public on 14 Feb 2023
31 Mar 2023 report: 48; public on 15 May 2023
30 Jun 2023 report: 72; public on 14 Aug 2023
30 Sep 2023 report: 70; public on 14 Nov 2023
31 Dec 2023 report: 71; public on 14 Feb 2024
31 Mar 2024 report: 84; public on 15 May 2024
30 Jun 2024 report: 84; public on 14 Aug 2024
30 Sep 2024 report: 93; public on 14 Nov 2024
31 Dec 2024 report: 87; public on 14 Feb 2025
31 Mar 2025 report: 83; public on 15 May 2025
30 Jun 2025 report: 91; public on 14 Aug 2025
30 Sep 2025 report: 88; public on 14 Nov 2025
31 Dec 2025 report: 98; public on 17 Feb 2026
31 Mar 2026 report: 103; public on 15 May 2026
30 Jun 2026 report: 94; public on 14 Aug 2026
30 Sep 2026 report: 107; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, fiscal year at $70.0M (31 Dec 2025), higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: -$12.0M).
  • Revenue per quarter: Revenue $0 in the latest quarter.
  • Capital spending per quarter: Capital spending $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 80 insider trades

No trades in the last 90 days; the latest was filed 20 Mar 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Mar 2025Growth N Biotech V and 1 other10% ownerSell5,784,292$2.07$12.0MForm 4
30 Aug 2024Versant Voyageurs I Parallel, L.P. and 3 others10% ownerSell221,600$6.32$1.4MForm 4
19 Oct 2023Growth N Biotech V and 1 other10% ownerBuy400,000$2.34$936KForm 4
7 Jul 2023Ra Capital Management, L.P. and 4 othersDirectorBuy935,850$5.00$4.7MForm 4
6 Jul 2023Ali BehbahaniDirectorBuy1,000,000$5.00$5.0MForm 4
3 Jul 2023BB Biotech AG and 1 other10% ownerBuy1,000,000$5.00$5.0MForm 4
29 Jun 2023Growth N Biotech V and 1 other10% ownerBuy1,740,000$5.49$9.6MForm 4
28 Jun 2023David M. EpsteinSEE REMARKSSellplanned in advance (10b5-1)25,000$6.70$168KForm 4

107 institutions reported shares at the end of Q3 2026, 66% of the shares outstanding; 22 opened a position, 10 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
NEA Management Company, LLC4.4M7.74%$8.4MNo change
BlackRock, Inc.4.3M7.48%$8.1M+384K+9.8%
T. Rowe Price Investment Management, Inc.3.9M6.83%-103K-2.5%
Acadian Asset Management LLC2.3M4.09%No change
Vanguard Capital Management LLC2.1M3.70%$4.0MNo change
Bank of America Corp2.0M3.56%$3.9M+1.6M+395%
Defilade Capital Management, L.P.1.8M3.08%$3.3M+96K+5.7%
Renaissance Technologies LLC1.7M2.87%$3.1M-310K-16%
Geode Capital Management, LLC1.2M2.17%$2.4M+28K+2.3%
Marshall Wace, LLP1.2M2.05%$2.2M+280K+31%

Company events

All 20 company events

Nothing in 12 months; the latest was filed 19 Mar 2025. Results releases and routine reports are left out.

FiledWhat happenedSource
19 Mar 2025Signed a major agreement8-K
7 Oct 2024Director or officer change8-K
11 Apr 2024Director or officer change8-K
18 Jan 2024Director or officer change8-K
18 Sep 2023Director or officer change8-K
30 Jun 2023Signed a major agreement8-K
19 Dec 2022Director or officer change8-K
7 Apr 2022Director or officer change8-K

The 5 newest of 89 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

18 Jul 2023confirmed

Confirmed across sources Insiders and Institutional holdings and Short interest and volume

Black Diamond Therapeutics (BDTX): had 3 insiders buy $24.2M of its shares on the open market within 30 days (4 filings); it also had 5.2M shares sold short in the 30 Jun 2023 report, 2.0× the same report last year; and it saw 30 13F filers open a new position in the quarter ended 30 Jun 2023, 2.5× the same quarter last year. Three unrelated kinds of activity within 38 days.

  • Insiders: Clustered insider buying, became public on 8 Jul 2023
  • Short interest and volume: Short interest spike, became public on 13 Jul 2023
  • Short interest and volume: Short interest spike, became public on 26 Jul 2023
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
2022-06-30: 2.6M2022-07-15: 2.5M2022-07-29: 2.3M2022-08-15: 2.2M2022-08-31: 2.2M2022-09-15: 2.1M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M
The 30 Jun 2023 report against the 24 reports before it. this reportearliernormal: 2.0M
See the evidence (4 changes)

Insiders: Clustered insider buying became public on 8 Jul 2023

Black Diamond Therapeutics had 3 insiders buy $24.2M of its shares on the open market within 30 days (4 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
4
Total bought
$24.2M
Window
8 Jun 2023 to 8 Jul 2023

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 13 Jul 2023

Black Diamond Therapeutics had 5.2M shares sold short in the 30 Jun 2023 report, 2.0× the same report last year.

This period
5.2M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
56K
How far from its usual level
+15.5
Same report last year
2.6M
History used
1,232 days
2022-06-30: 2.6M2022-07-15: 2.5M2022-07-29: 2.3M2022-08-15: 2.2M2022-08-31: 2.2M2022-09-15: 2.1M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M
the 30 Jun 2023 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jul 2023

Black Diamond Therapeutics had 3.2M shares sold short in the 14 Jul 2023 report, 1.3× the same report last year.

This period
3.2M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
56K
How far from its usual level
+5.7
Same report last year
2.5M
History used
1,246 days
2022-07-15: 2.5M2022-07-29: 2.3M2022-08-15: 2.2M2022-08-31: 2.2M2022-09-15: 2.1M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M
the 14 Jul 2023 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

Black Diamond Therapeutics saw 30 13F filers open a new position in the quarter ended 30 Jun 2023, 2.5× the same quarter last year.

This period
30 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
9.5
Typical spread (median absolute deviation)
3.5
How far from its usual level
+4.0
Same quarter last year
12
History used
1,186 days
2021-06-30: 222021-09-30: 112021-12-31: 142022-03-31: 82022-06-30: 122022-09-30: 82022-12-31: 52023-03-31: 12023-06-30: 30
the quarter ended 30 Jun 20238 earlier quartersnormal: 9.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 7 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 7 Oct 2024Filings record

    Director or officer change

  3. 11 Apr 2024Filings record

    Director or officer change

  4. 18 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 18 Jan 2024Filings record

    Director or officer change

  6. 11 Jan 2024Short interest and volume change

    had 3.6M shares sold short in the 29 Dec 2023 report, 1.7× the same report last year.

    Same report last year: 2.1M; its normal report is 2.0M.

    See the evidence
    This period
    3.6M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    239K
    How far from its usual level
    +4.6
    Same report last year
    2.1M
    History used
    1,414 days
    2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M2023-07-31: 1.0M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.4M2023-09-29: 2.4M2023-10-13: 3.0M2023-10-31: 3.4M2023-11-15: 3.4M2023-11-30: 3.4M2023-12-15: 3.6M2023-12-29: 3.6M
    the 29 Dec 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  7. 28 Dec 2023Short interest and volume change

    had 3.6M shares sold short in the 15 Dec 2023 report, 1.8× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    3.6M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    71K
    How far from its usual level
    +8.3
    Same report last year
    2.0M
    History used
    1,400 days
    2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M2023-07-31: 1.0M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.4M2023-09-29: 2.4M2023-10-13: 3.0M2023-10-31: 3.4M2023-11-15: 3.4M2023-11-30: 3.4M2023-12-15: 3.6M
    the 15 Dec 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 12 Dec 2023Short interest and volume change

    had 3.4M shares sold short in the 30 Nov 2023 report, 1.7× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    3.4M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    48K
    How far from its usual level
    +7.3
    Same report last year
    2.0M
    History used
    1,385 days
    2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M2023-07-31: 1.0M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.4M2023-09-29: 2.4M2023-10-13: 3.0M2023-10-31: 3.4M2023-11-15: 3.4M2023-11-30: 3.4M
    the 30 Nov 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 28 Nov 2023Short interest and volume change

    had 3.4M shares sold short in the 15 Nov 2023 report, 1.7× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    3.4M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    45K
    How far from its usual level
    +7.0
    Same report last year
    2.0M
    History used
    1,370 days
    2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M2023-07-31: 1.0M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.4M2023-09-29: 2.4M2023-10-13: 3.0M2023-10-31: 3.4M2023-11-15: 3.4M
    the 15 Nov 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 10 Nov 2023Short interest and volume change

    had 3.4M shares sold short in the 31 Oct 2023 report, 1.6× the same report last year.

    Same report last year: 2.1M; its normal report is 2.0M.

    See the evidence
    This period
    3.4M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    45K
    How far from its usual level
    +6.9
    Same report last year
    2.1M
    History used
    1,355 days
    2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M2023-07-31: 1.0M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.4M2023-09-29: 2.4M2023-10-13: 3.0M2023-10-31: 3.4M
    the 31 Oct 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 25 Oct 2023Short interest and volume change

    had 3.0M shares sold short in the 13 Oct 2023 report, 1.3× the same report last year.

    Same report last year: 2.2M; its normal report is 2.0M.

    See the evidence
    This period
    3.0M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    45K
    How far from its usual level
    +5.0
    Same report last year
    2.2M
    History used
    1,337 days
    2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M2023-07-31: 1.0M2023-08-15: 1.1M2023-08-31: 1.1M2023-09-15: 1.4M2023-09-29: 2.4M2023-10-13: 3.0M
    the 13 Oct 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 20 Oct 2023Insiders record

    BIOTECH GROWTH N V (ten percent owner) and 1 other(s) bought 400,000 shares of BDTX ($936,000) (dated 19 Oct 2023)

  13. 18 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 18 Sep 2023Filings record

    Director or officer change

  15. 14 Aug 2023Institutional holdings change

    saw 30 13F filers open a new position in the quarter ended 30 Jun 2023, 2.5× the same quarter last year.

    Same quarter last year: 12; its normal quarter is 9.5.

    See the evidence
    This period
    30 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    9.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.0
    Same quarter last year
    12
    History used
    1,186 days
    2021-06-30: 222021-09-30: 112021-12-31: 142022-03-31: 82022-06-30: 122022-09-30: 82022-12-31: 52023-03-31: 12023-06-30: 30
    the quarter ended 30 Jun 20238 earlier quartersnormal: 9.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 26 Jul 2023Short interest and volume change

    had 3.2M shares sold short in the 14 Jul 2023 report, 1.3× the same report last year.

    Same report last year: 2.5M; its normal report is 2.0M.

    See the evidence
    This period
    3.2M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    56K
    How far from its usual level
    +5.7
    Same report last year
    2.5M
    History used
    1,246 days
    2022-07-15: 2.5M2022-07-29: 2.3M2022-08-15: 2.2M2022-08-31: 2.2M2022-09-15: 2.1M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M
    the 14 Jul 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 18 Jul 2023several at once

    had 3 insiders buy $24.2M of its shares on the open market within 30 days (4 filings); it also had 5.2M shares sold short in the 30 Jun 2023 report, 2.0× the same report last year; and it saw 30 13F filers open a new position in the quarter ended 30 Jun 2023, 2.5× the same quarter last year. Three unrelated kinds of activity within 38 days.

    See the evidence (4 changes)

    Insiders: Clustered insider buying became public on 8 Jul 2023

    Black Diamond Therapeutics had 3 insiders buy $24.2M of its shares on the open market within 30 days (4 filings).

    Independent buyers
    3
    Purchase filings (Form 4, code P)
    4
    Total bought
    $24.2M
    Window
    8 Jun 2023 to 8 Jul 2023

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Short interest and volume: Short interest spike became public on 13 Jul 2023

    Black Diamond Therapeutics had 5.2M shares sold short in the 30 Jun 2023 report, 2.0× the same report last year.

    This period
    5.2M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    56K
    How far from its usual level
    +15.5
    Same report last year
    2.6M
    History used
    1,232 days
    2022-06-30: 2.6M2022-07-15: 2.5M2022-07-29: 2.3M2022-08-15: 2.2M2022-08-31: 2.2M2022-09-15: 2.1M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M
    the 30 Jun 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jul 2023

    Black Diamond Therapeutics had 3.2M shares sold short in the 14 Jul 2023 report, 1.3× the same report last year.

    This period
    3.2M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    56K
    How far from its usual level
    +5.7
    Same report last year
    2.5M
    History used
    1,246 days
    2022-07-15: 2.5M2022-07-29: 2.3M2022-08-15: 2.2M2022-08-31: 2.2M2022-09-15: 2.1M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M2023-07-14: 3.2M
    the 14 Jul 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

    Black Diamond Therapeutics saw 30 13F filers open a new position in the quarter ended 30 Jun 2023, 2.5× the same quarter last year.

    This period
    30 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    9.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.0
    Same quarter last year
    12
    History used
    1,186 days
    2021-06-30: 222021-09-30: 112021-12-31: 142022-03-31: 82022-06-30: 122022-09-30: 82022-12-31: 52023-03-31: 12023-06-30: 30
    the quarter ended 30 Jun 20238 earlier quartersnormal: 9.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  18. 13 Jul 2023Short interest and volume change

    had 5.2M shares sold short in the 30 Jun 2023 report, 2.0× the same report last year.

    Same report last year: 2.6M; its normal report is 2.0M.

    See the evidence
    This period
    5.2M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    56K
    How far from its usual level
    +15.5
    Same report last year
    2.6M
    History used
    1,232 days
    2022-06-30: 2.6M2022-07-15: 2.5M2022-07-29: 2.3M2022-08-15: 2.2M2022-08-31: 2.2M2022-09-15: 2.1M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.1M2022-11-15: 2.0M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 2.1M2023-01-13: 2.0M2023-01-31: 2.0M2023-02-15: 2.0M2023-02-28: 2.0M2023-03-15: 2.0M2023-03-31: 2.0M2023-04-14: 2.0M2023-04-28: 2.0M2023-05-15: 1.9M2023-05-31: 1.9M2023-06-15: 1.9M2023-06-30: 5.2M
    the 30 Jun 2023 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 8 Jul 2023Insiders change

    had 3 insiders buy $24.2M of its shares on the open market within 30 days (4 filings).

    Who bought: Behbahani Ali.

    See the evidence (4 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    4
    Total bought
    $24.2M
    Window
    8 Jun 2023 to 8 Jul 2023

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  20. 8 Jul 2023Insiders record

    RA CAPITAL MANAGEMENT, L.P. (director) and 4 other(s) bought 935,850 shares of BDTX ($4.7M) (dated 7 Jul 2023)

  21. 7 Jul 2023Insiders record

    Behbahani Ali (director) bought 1,000,000 shares of BDTX ($5.0M) (dated 6 Jul 2023)

  22. 4 Jul 2023Insiders record

    BB BIOTECH AG (ten percent owner) and 1 other(s) bought 1,000,000 shares of BDTX ($5.0M) (dated 3 Jul 2023)

  23. 30 Jun 2023Insiders record

    BIOTECH GROWTH N V (ten percent owner) and 1 other(s) bought 1,740,000 shares of BDTX ($9.6M) (dated 29 Jun 2023)

  24. 24 Dec 2022Insiders record

    Ni Fang (SEE REMARKS) bought 56,363 shares of BDTX ($72,345) (dated 23 Dec 2022)

  25. 19 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 19 Dec 2022Filings record

    Director or officer change

  27. 3 Nov 2022Insiders record

    BIOTECH GROWTH N V (ten percent owner) and 1 other(s) bought 99,801 shares of BDTX ($224,552) (dated 2 Nov 2022)

  28. 1 Nov 2022Insiders record

    BB BIOTECH AG (ten percent owner) and 1 other(s) bought 364,652 shares of BDTX ($735,521) (dated 31 Oct 2022)

  29. 26 Oct 2022Insiders record

    BB BIOTECH AG (ten percent owner) and 1 other(s) bought 87,850 shares of BDTX ($132,654) (dated 25 Oct 2022)

  30. 22 Oct 2022Insiders record

    BB BIOTECH AG (ten percent owner) and 1 other(s) bought 131,423 shares of BDTX ($178,852) (dated 21 Oct 2022)

  31. 1 Jul 2022Insiders record

    Ni Fang (SEE REMARKS) bought 25,000 shares of BDTX ($61,000) (dated 30 Jun 2022)

  32. 30 Apr 2022Insiders record

    BIOTECH GROWTH N V (ten percent owner) and 1 other(s) bought 405,711 shares of BDTX ($1.1M) (dated 29 Apr 2022)

  33. 21 Apr 2022Insiders record

    BIOTECH GROWTH N V (ten percent owner) and 1 other(s) bought 300,000 shares of BDTX ($979,500) (dated 20 Apr 2022)

  34. 15 Apr 2022Insiders record

    BIOTECH GROWTH N V (ten percent owner) and 1 other(s) bought 252,556 shares of BDTX ($879,125) (dated 14 Apr 2022)

  35. 7 Apr 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 7 Apr 2022Filings record

    Director or officer change

  37. 22 Nov 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 22 Nov 2021Filings record

    Director or officer change

  39. 10 Aug 2021Filings record

    Director or officer change

  40. 5 Aug 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 63 entries; narrow the window or the kind of data to see older ones.

Not listed: 130 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001701541
Ticker
BDTX
Domain
blackdiamondtherapeutics.com
Hq location
MA|CAMBRIDGE|02142 (1 unverified)
Name
Aset Therapeutics, Inc., Black Diamond Therapeutics, Inc.
  • SEC Form 13F institutional holdings243 data points31 Mar 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)88 records28 Mar 2017 to 10 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)462 data points31 Dec 2017 to 5 Nov 2026
  • SEC Form 4 insider transactions80 records, 228 data points3 Feb 2020 to 20 Mar 2025
  • FINRA short interest (twice monthly)482 data points14 Feb 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3426 data points30 Jan 2020 to 20 Nov 2026